Nothing Special   »   [go: up one dir, main page]

WO2007002447A3 - Compositions for treating rosacea - Google Patents

Compositions for treating rosacea Download PDF

Info

Publication number
WO2007002447A3
WO2007002447A3 PCT/US2006/024551 US2006024551W WO2007002447A3 WO 2007002447 A3 WO2007002447 A3 WO 2007002447A3 US 2006024551 W US2006024551 W US 2006024551W WO 2007002447 A3 WO2007002447 A3 WO 2007002447A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
treating rosacea
disclosed
rosacea
pharmaceutical
Prior art date
Application number
PCT/US2006/024551
Other languages
French (fr)
Other versions
WO2007002447A2 (en
Inventor
Steven L Basta
Adam D Gridley
Original Assignee
Bioform Medical Inc
Steven L Basta
Adam D Gridley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioform Medical Inc, Steven L Basta, Adam D Gridley filed Critical Bioform Medical Inc
Publication of WO2007002447A2 publication Critical patent/WO2007002447A2/en
Publication of WO2007002447A3 publication Critical patent/WO2007002447A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed are pharmaceutical and cosmetic compositions containing as active ingredients a combination of at least one oxy group-bearing aromatic aldehyde compound and an additional cosmetically or pharmaceutically effective agent that is effective against rosacea. Uses of these compositions are also disclosed.
PCT/US2006/024551 2005-06-23 2006-06-23 Compositions for treating rosacea WO2007002447A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69353605P 2005-06-23 2005-06-23
US60/693,536 2005-06-23

Publications (2)

Publication Number Publication Date
WO2007002447A2 WO2007002447A2 (en) 2007-01-04
WO2007002447A3 true WO2007002447A3 (en) 2007-02-22

Family

ID=37441235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/024551 WO2007002447A2 (en) 2005-06-23 2006-06-23 Compositions for treating rosacea

Country Status (1)

Country Link
WO (1) WO2007002447A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008351422A1 (en) * 2008-02-27 2009-09-03 Allergan, Inc. Dapsone to treat rosascea
EP2313783A2 (en) * 2008-07-18 2011-04-27 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
US20110305747A1 (en) * 2009-07-30 2011-12-15 Allergan, Inc. Combination of dapsone with other anti-acne agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006537A1 (en) * 1988-01-15 1989-07-27 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
WO2003043621A1 (en) * 2001-11-16 2003-05-30 Cutanix Corporation Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
WO2004103233A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006537A1 (en) * 1988-01-15 1989-07-27 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
WO2003043621A1 (en) * 2001-11-16 2003-05-30 Cutanix Corporation Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes
WO2004103233A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US20040242588A1 (en) * 2003-05-27 2004-12-02 Jack Dejovin Compounds, formulations, and methods for treating or preventing rosacea

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SKINCARERX: "Cutanix Dramtic Relief for Sensitive Skin and Rosacea", 3 April 2005 (2005-04-03), pages 1 - 2, XP002409824, Retrieved from the Internet <URL:http://web.archive.org/web/20050403042254/http://skincarerx.com/cutanix.html> [retrieved on 20061130] *

Also Published As

Publication number Publication date
WO2007002447A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2004089357A3 (en) Anti-fungal formulation of triterpene and essential oil
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2005079143A3 (en) Topical formulations for the treatment of skin conditions
WO2006056711A3 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007022344A3 (en) Methods and compositions for the preventioin and treatment of kidney disease
WO2007046097A3 (en) Topical compositions for the treatment of depilation-induced skin irritation or prevention thereof
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2005117895A8 (en) Compositions comprising meloxicam
WO2006083780A3 (en) Glucuronidated nebivolol
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
WO2006121964A3 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
BR0209327A (en) Composition for treatment of drug-induced constipation
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2008025830A3 (en) Pharmaceutical and sunscreen compositions comprising caspase-14
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2002036129A3 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
WO2003035080A3 (en) A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06773873

Country of ref document: EP

Kind code of ref document: A2